Skip to main content
Fig. 9 | Translational Neurodegeneration

Fig. 9

From: Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease

Fig. 9

MiR-504-3p targets p39. a Sequences of the WT and mutant 3′UTR of p39. The 3′UTR of p39 harbors a miR-504-3p-binding site. b Results of the luciferase reporter assay using N2a cells cotransfected with a WT or mutant p39 3′UTR plasmid and miR-504-3p mimics or NC mimics. Data are presented as the means ± standard errors of three independent experiments (**P < 0.01 vs. the WT p39 group). c Hippocampal lysates from 10-month-old hTau + SA and hTau + MT mice were subjected to immunoblotting analysis with an anti-p39 or anti-β-actin antibody. d, f N2a cells were transduced with NC or miR-504-3p mimics. The protein (d) and mRNA (f) expression of p39 were measured by immunoblotting and qRT-PCR, respectively. β-actin was used as an internal control for immunoblotting, while 18S rRNA was used as an internal reference for qRT-PCR. Data are presented as the means ± standard errors of three independent experiments (**P < 0.01, ***P < 0.001 vs. the untreated group). e, g N2a cells were transduced with NC or a miR-504-3p inhibitor and then treated with melatonin. The protein (e) and mRNA (g) expression of p39 were measured by immunoblotting and qRT-PCR, respectively. Data are presented as the means ± standard errors of three independent experiments (**P < 0.01, ****P < 0.0001 vs. the group treated with melatonin alone)

Back to article page